METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests if early chemo boosts survival for advanced prostate cancer
Disease control CompletedThis large, completed study aimed to see if adding chemotherapy (docetaxel) to standard hormone-blocking therapy could help men with prostate cancer that had spread to other parts of the body. It involved 790 men and directly compared the combination treatment against hormone the…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo shows promise in slowing advanced prostate cancer
Disease control CompletedThis large, completed Phase 3 trial tested whether adding the drug enzalutamide to standard hormone therapy (ADT) was better than hormone therapy alone for men whose prostate cancer had already spread. The main goal was to see if the combination could delay the cancer from gettin…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Prostate cancer drug combo trial halted early
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) would help men with metastatic prostate cancer that still responds to hormones. The study enrolled 186 Chinese participants and aimed to see if the co…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for slowing advanced prostate cancer
Disease control CompletedThis large, completed Phase 3 trial tested whether adding a new drug called darolutamide to standard hormone therapy and chemotherapy could help men with prostate cancer that has spread (metastasized). The study involved over 1,300 participants and aimed to see if this combinatio…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
AI model predicts prostate cancer treatment success from scans
Knowledge-focused CompletedThis study looked back at medical records and PET scans from 168 men with advanced prostate cancer who received standard first-line treatment. Researchers created a prediction model that combines scan results with patient information to estimate how quickly and effectively treatm…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC